client logo
Version: 1.0.0 | Published: 7 Oct 2026 | Updated: 42 days ago

Checkpoint Inhibitor-induced Liver Injury (ChILI)

Dataset

Documentation

Description:
Checkpoint inhibitor-induced liver injury (ChILI) is a new incompletely understood category of hepatotoxicity which is distinct from other types of drug-induced liver injury (DILI) such as direct or idiosyncratic DILI. The data regarding the incidence and risk factors is lacking. Therefore, "in-depth phenotyping" together with data from the control group exposed to checkpoint inhibitors (CPI) is necessary to develop refined algorithms incorporating CPI-related factors, host genetic and environmental risk factors that would enable pre-empting ChILI. The aim of the study is to enroll two deeply phenotyped cohorts (patients who developed ChILI and patients who are starting checkpoint inhibitors) and obtain biological samples at multiple time points. Collection and storage of biological samples (blood, urine, stool) from patients with ChILI at three-time points (the day of liver injury, 1 week, and 1 month after). The investigators will perform a liver biopsy when it is clinically indicated. Collection and storage of biological samples (blood, urine, and stool) from control patients at two-time points (before starting CPIs and 6 to 14 weeks after commencing treatment) Primary outcome measures: - Incidence of checkpoint inhibitor-induced liver injury (ChILI) and other immune-mediated adverse reactions - Identify novel biomarkers associated with the diagnosis of ChILI - The investigators plan assessment of proposed circulating biomarkers including cytokines, microRNAs (miR-122, miR-4270 and miR-4463), total cytokeratin 18 (K18), macrophage colony-stimulating factor receptor (MCSFR), and any others identified in subsequent publications and measure their diagnostic and prognostic accuracy using the area under the receiver operating curve (AUROC). ChILI group: Adults with cancer receiving checkpoint inhibitors (CTLA-4, PD-1 or PD L1 inhibitor) as monotherapy or combination (without chemotherapy) and developed acute liver injury secondary to checkpoint inhibitor. Collection and storage of biological samples (blood, urine, stool) from patients with ChILI at three-time points (the day of liver injury, 1 week, and 1 month after). The investigators will perform a liver biopsy when it is clinically indicated. Control Group: Patients with malignant melanoma, renal cell carcinoma, non-small cell lung cancer or any other cancer, receiving single or combination therapy using checkpoint inhibitors (CPIs). Collection and storage of biological samples (blood, urine, and stool) from control patients at two-time points (before starting CPIs and 6 to14 weeks after commencing treatment)

Coverage

Spatial:
England and Scotland
Typical Age Range:
18-150
Follow Up:
1 - 10 Years

Provenance

Origin

Purposes:
Study
Sources:
  • EPR
  • Other
Collection Situations:
  • Cohort, study, trial
  • Secondary care - Outpatients
  • Secondary care - In-patients

Temporal

Accrual Periodicity:
Irregular
Start Date:
13 October 2020
End Date:
30 November 2027
Time Lag:
Variable

Accessibility

Access

Access Rights:
In progress
Delivery Lead Time:
Variable
Jurisdictions:
UK
Data Controller:
University of Nottingham
Data Processor:
Dr Jane Grove; Professor Guruprasad Aithal

Usage

Data Use Limitations:
User-specific restrictions
Data Use Requirements:
User-specific restriction
Resource Creators:
To be confirmed

Format and Standards

Vocabulary Encoding Schemes:
LOCAL
Conforms To:
LOCAL
Languages:
en
Formats:
  • text/csv
  • other

Observations

Statistical Population
Population Description
Population Size
Measured Property
Observation Date
Persons
213
Count
23 July 2026